ABMC Announces Two Patent Awards.
KINDERHOOK, N.Y. -- American Bio Medica medica (māˑ·dē·k Corporation (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ABMC ABMC American Battle Monuments Commission
ABMC Alexian Brothers Medical Center (Illinois)
ABMC Aviation Battle Management Concept
ABMC Arrowbear Music Camp (California) ) has been notified by the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent & Trademark office that it will be granted two patents; one for its oral fluid drug testing product line and the other for its all inclusive urine point of collection drug test cup product line.
U.S. Patent Number 7,507,374 relates to the testing of a saliva saliva
Thick, colourless fluid constantly present in the mouth, composed of water, mucus, proteins, mineral salts, and amylase, an enzyme that breaks down starches. One to two litres are produced daily by the salivary glands. (oral fluid) sample for drugs of abuse, more particularly to a device and process which permits the saliva sample to be treated and incubated for a predetermined pre·de·ter·mine
v. pre·de·ter·mined, pre·de·ter·min·ing, pre·de·ter·mines
1. To determine, decide, or establish in advance: period of time prior to being introduced to an immunoassay Immunoassay
An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. test strip.
US Patent Number 7,507,373 covers the Company's all-inclusive cup product line and relates to an assay device for the testing of liquid samples for determining the presence of undesirable constituents, more particularly to a test device having a container for retaining a liquid sample and test strips within the container for indicating visually the presence of particular drugs of abuse.
With these grants, ABMC's intellectual property portfolio for its drug of abuse testing line increases to 10 United States patents and 14 foreign patents, in addition to a number of pending patent applications both within the US and internationally.
For more information on American Bio Medica Corporation or its products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen[R], Rapid ONE[R], Rapid TEC[R], RDS (1) (Remote Data Services) A set of programming interfaces from Microsoft that enables users to update data on the Internet or intranets from their ActiveX-enabled browser. [R] InCup[R], Rapid TOX TOX Total Organic Halides
TOX Total Organic Halogens
TOX Toxxulia Forest (Everquest)
TOX Thermal Oxide
TOX Tetradichlorooxylene [R] and Rapid TOX Cup[R] products test for the presence or absence of drugs of abuse in urine, while OralStat[R] and Rapid STAT[TM] tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader[R] is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
This release may contain forward-looking statements forward-looking statement
A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development, regulatory approvals and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2007, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.